ANNUAL REPORT

NTDs

2023

World Health Organization
Ethiopia
CONTENTS

SECTION 1 .......................................................................................................................... 2
GUINEA WORM ERADICATION PROGRAMME .................................................................. 2
  Background .......................................................................................................................... 2
  National level program coordination .............................................................................. 3
  Capacity Building .............................................................................................................. 3
  House to House Active Case Search and Health Education ............................................ 4
  Integration of Dracunculiasis case search with immunization campaigns ..................... 5
  Dracunculiasis Surveillance at entry points ..................................................................... 5
  Active case finding and health education in large public gathering places ..................... 6
  Distribution of Information, Education, and Communication (IEC) materials ............... 7
  Rumors reporting and investigation ................................................................................. 7
  Performance monitoring and assessment of cash reward awareness .............................. 9
  Documentation of GWD surveillance data for certification ............................................ 10
  Direct Financial Cooperation (DFC) ................................................................................. 11

SECTION 2 .......................................................................................................................... 12
PREVENTIVE CHEMOTHERAPY NTDS ............................................................................. 12
  Background ......................................................................................................................... 12
  Key Achievements in 2023 ............................................................................................... 12
  KEY ACHIEVEMENTS BY DISEASE .............................................................................. 15
  Lymphatic Filariasis ......................................................................................................... 15
  Onchocerciasis ................................................................................................................. 16
  Schistosomiasis ................................................................................................................. 16
  Soil Transmitted Helminthiasis ......................................................................................... 16
  Trachoma ........................................................................................................................... 16
  Summary of Financial Support ......................................................................................... 17

SECTION 3 .......................................................................................................................... 18
CASE MANAGEMENT NTDs ............................................................................................... 18
  BACKGROUND ..................................................................................................................... 18
  SUMMARY OF KEY ACHIEVEMENTS: ........................................................................... 18
  SUMMARY OF FINANCIAL SUPPORT ........................................................................... 21
  Action Pictures ................................................................................................................... 22
Executive summary

This report represents the WHO-supported NTDs program activities and key performances in 2023. It is categorized into three sections: The first section states on the disease targeted for eradication (Guinea worm disease); the second section is on the Preventive Chemotherapy (PC)-NTDs (Trachoma, Schistosomiasis, Soil Transmitted Helminthiasis, Onchocerciasis and Lymphatic Filariasis) and the third section is focused on the case management NTDs (Leishmaniasis, Leprosy, Human African Trypanosomiasis, Noma and other skin NTDs).

WHO sustained active Guinea worm disease surveillance in seven refugee camps of Gambella and Benishangul Gumuz regions hosting more than 450,000 refugee populations. In 2023, the country didn’t report any human cases except for one dog infection which is contained. This gives hope for the country to interrupt the transmission of the disease very soon.

WHO supported Ministry of Health in scaling up and scaling down interventions notably on Mass Drug Administration (MDA) campaigns, mapping/surveys for PC NTDs, and facilitated the PC NTD drug donation through the Joint Application Package (JAP).

After 30 years of zero reports, the country faced the re-emergence of Human African Trypanosomiasis (HAT) and reported the first case in August 2022. Subsequently, a total of 8 cases were reported until June 2023. The three levels of WHO supported the outbreak response successfully. Since June 2023, there has been no case of HAT reported so far. The country office also managed to advocate for the initiation of Noma control program in Ethiopia, mobilized funding from WHO African regional office and provided training for 111 primary healthcare workers in four regions. The visceral leishmaniasis case fatality rate in 2023 had reduced to 2.7% from 4.6% in 2022. There were outbreaks of visceral and cutaneous Leishmaniasis in Southern Nations and Somali regions, respectively. These outbreaks were successfully responded.

Overall, apart from the technical assistance, financial support of 358,060 USD was provided to the MOH, regions, and Universities either by Direct Financial Cooperation (DFC) or Direct Implementation (DI) for various NTDs implementations.
SECTION 1

GUINEA WORM ERADICATION PROGRAMME

Background

During 2023 Ethiopia’s Dracunculiasis Eradication Programme (EDEP) reported zero human case and one animal infection from Gambella region. This represents significant progress as compared to one human case and three animal infections in 2022 (figure 1 shows human and animal infections in the past 4 years). In 2023, the WHO country office provided technical and financial support for maintaining optimal level of dracunculiasis surveillance in seven refugee camps in Gambella and Benishangul Gumuz regions hosting over 450,000 refugees from dracunculiasis - endemic country South Sudan. The refugee camps supported by WHO include Kule, Jewi, Okugo, Nguenyyiel, Terkedi, Tsore, and Sherkole. Likewise, The Carter Center (TCC) provided technical and financial support for dracunculiasis eradication program in endemic and high-risk districts of the country. This report summarizes major activities and achievement of WHO supported Guinea worm eradication program in 2023.

Figure 1 Human cases and animal infections reported from 2020 to 2023 in Ethiopia
National level program coordination

- WHO supported the development of EDEP annual action plan for 2023. The operational plan was developed by convening a meeting with all stakeholders and partners supporting the eradication effort. This enabled partners and stakeholders to align their plan accordingly. The operational plan was developed based on the draft EDEP strategic plan and national NTD strategic plan (2021-2025).

- The 2022 Annual Review Meetings was also convened in Gambella region in January 2023 where program performances were reviewed, and recommendations formulated. The Annual Programme managers meeting in Atlanta, USA was also attended virtually in March 2023. Ethiopia had presented the key performances on the eradication program and new innovative ways of vector control by using environmental modification/management strategies. WHO technically and financially supported the review meeting preparations.

- The EDEP Technical Working Group was convened on monthly bases, monitored program performances, identified gaps, and addressed issues of concern accordingly.

Capacity Building

During 2023, WHO supported training of a total of 185 health professionals on Guinea worm disease surveillance and other locally relevant neglected tropical diseases in Gambella and Benishangul Gumuz regions. Training participants were recruited from health facilities in seven refugee camps, hosting communities, districts sharing common border with South Sudan, and health facilities located in gold mining areas attracting migrant workers from South Sudan. Besides, WHO’s Guinea worm field officers conducted sensitization for 432 health professionals attending other health program training workshops and during field visit in refugee camps.
During the reporting year WHO supported annual standard training for a total of 468 community health workers and supervisors in seven refugee camps in Gambella and Benishangul Gumuz regions. On top of this, WHO’s Guinea worm field officers conducted replacement trainings and sensitization sessions for 731 community health workers. In 2023, all (100%) blocks (villages) in seven refugee camps have had at least one community health worker trained in Guinea worm disease surveillance.

**House to House Active Case Search and Health Education**

In 2023, WHO’s Guinea worm field officers provided technical support on monthly house to house active case search and provision of health education in seven refugee camps. As showed in the below table, on average, every month, nearly 13,000 households and over 72,000 people were reached by house-to-house case search and health education, respectively.
Table 1: Number of households and people covered by active case search and health education in 7 refugee camps in 2023.

<table>
<thead>
<tr>
<th>Month</th>
<th>No of HHs visited</th>
<th>No of people reached</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan</td>
<td>14,801</td>
<td>80,622</td>
</tr>
<tr>
<td>Feb</td>
<td>18,645</td>
<td>96,443</td>
</tr>
<tr>
<td>March</td>
<td>15,281</td>
<td>78,300</td>
</tr>
<tr>
<td>April</td>
<td>15,230</td>
<td>85,881</td>
</tr>
<tr>
<td>May</td>
<td>13,852</td>
<td>76,290</td>
</tr>
<tr>
<td>June</td>
<td>15,037</td>
<td>72,756</td>
</tr>
<tr>
<td>July</td>
<td>10,678</td>
<td>50,160</td>
</tr>
<tr>
<td>August</td>
<td>10,415</td>
<td>51,544</td>
</tr>
<tr>
<td>September</td>
<td>10,350</td>
<td>51,875</td>
</tr>
<tr>
<td>October</td>
<td>8,380</td>
<td>74,676</td>
</tr>
<tr>
<td>November</td>
<td>7,580</td>
<td>62,954</td>
</tr>
<tr>
<td>December</td>
<td>15,660</td>
<td>85,942</td>
</tr>
<tr>
<td>Average</td>
<td>12,992</td>
<td>72,287</td>
</tr>
</tbody>
</table>

**Integration of Dracunculiasis case search with immunization campaigns**

In 2023, WHO supported integration of Guinea worm disease surveillance with measles, COVID-19 vaccination, and onchocerciasis Mass Drug Administration (MDA) campaigns. During these campaigns, a total of 70,642 people were interviewed and provided with health education on Guinea worm disease and the cash reward for reporting cases.

**Dracunculiasis Surveillance at entry points**

WHO supported Guinea worm disease surveillance at six entry points in Gambella region (Akobo Tiergol, Buribiey, Pagak, Wankey, Pochala, and Raad) and one entry point in Benishangul Gumuz region (Kumruk). The WHO support on GWD surveillance at entry
points include on-site training of health professionals, investigation of rumors/suspected cases of GWD and provision of surveillance forms and IEC materials.

**Figure 4 GWD case search and awareness raising in Kumuruk entry point**

![Image](image1)

**Active case finding and health education in large public gathering places.**

WHO supported the dissemination of GWD and cash reward messages using mobile van with mega loudspeaker in seven local languages such as Arabic, Denka, Fugn, Meban, Nuer, Oduk, and Swahili. A total of **53** health education sessions were conducted in large public gathering places such as schools, ration distribution sites, and marketplaces in all refugee camps. Over **180,000** people were reached and provided with health education.

**Figure 5 GWD and cash reward awareness raising campaign in refugee camps**

![Image](image2)
Distribution of Information, Education, and Communication (IEC) materials

WHO supported the development, printing, and distribution of 3,600 GWD cash reward posters which were publicized in every block (village), school, health centre, market, and other large public gathering places within the various refugee camps. On top of this 2,800 Guinea worm recognition cards and 1,000 Guinea worm T-shirts were distributed to the community health workers and health professionals. Similarly, 150 GWD case definitions and 50 GWD standard operation procedures were provided to the health facilities within the refugee camps.

Figure 6 IEC materials distributed in refugee camps

Rumors reporting and investigation.

Increased detection and reporting of rumours and suspected cases is a key indicator of Guinea worm disease surveillance. In 2023, a total of 2,554 rumours and suspected cases were reported from seven refugee camps. Of these, 2,535 (99%) of rumours and suspected cases were investigated within 24 hours. None of the rumours and suspected cases were confirmed as a case of Guinea worm disease. WHO’s Guinea worm field officers had also participated and supported the investigation of highly suspected human cases and animal infections in the endemic areas.
Table 2 Number of rumors and suspected cases reported and investigated within 24 hours by refugee camp, 2023.

<table>
<thead>
<tr>
<th>Refugee Camp</th>
<th>Rumors reported and investigated</th>
<th>Rumors investigated within 24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kule</td>
<td>196</td>
<td>196</td>
</tr>
<tr>
<td>Jewi</td>
<td>438</td>
<td>436</td>
</tr>
<tr>
<td>Okugo</td>
<td>78</td>
<td>78</td>
</tr>
<tr>
<td>Nguenyyiel</td>
<td>305</td>
<td>305</td>
</tr>
<tr>
<td>Terkedie</td>
<td>491</td>
<td>487</td>
</tr>
<tr>
<td>Sherkole</td>
<td>467</td>
<td>462</td>
</tr>
<tr>
<td>Tsore</td>
<td>579</td>
<td>571</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,554</strong></td>
<td><strong>2,535 (99%)</strong></td>
</tr>
</tbody>
</table>

Figure 7 Number of rumors and suspected cases reported and investigated by month in refugee camps, 2023.
**Performance monitoring and assessment of cash reward awareness**

WHO monitored program performance through monthly supervisions in refugee camps, review of reports, periodic meetings with community health workers/supervisors and spot check awareness assessment in households. Standard awareness surveys were conducted in six refugee camps through interview of 2,720 individuals, of which 2,351 (86%) heard about the existence of the cash reward and 2073 (76%) knew the correct amount the reward.

**Figure 8: Percentage of people heard about the cash reward and people who knew the correct amount of reward by refugee camp, 2023.**

![Graph showing percentage of people heard about existence of cash reward and people who knew the correct amount of cash reward by refugee camp]

EDEP provides 500 Ethiopian birr for reporting infected animals. During the awareness survey in four refugee camps of Gambella region, a total of 1,600 individuals were asked on the cash reward awareness. Of these 64% heard about the existence of cash reward for reporting infected animals and 60% knew the correct amount of the reward.
Figure 9: Percentage of people heard about existence of cash reward for reporting infected animal and people who knew the correct amount of cash reward by refugee camp, 2023.

**Documentation of GWD surveillance data for certification**

To strengthen proper documentation of GWD surveillance, WHO provided all essential data collection, compilation, and reporting forms, supervisory checklists, and file folders to all refugee camps. All zones and blocks under active surveillance submitted their GWD surveillance report to their respective refugee camps and all refugee camps submitted monthly report to the regional health bureaus (RHB). All reports were kept in file folders and properly archived in the refugee camps and RHBs for future review by international certification teams. WHO supported the EDEP to update and maintain electronic data as part of strengthening documentations for subsequent certification.
## Direct Financial Cooperation (DFC)

<table>
<thead>
<tr>
<th>SN</th>
<th>Recipient</th>
<th>Amount</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>EPHI</td>
<td>1,679,911</td>
<td>To support GWEP activities</td>
</tr>
<tr>
<td>2</td>
<td>Gambella</td>
<td>721,875</td>
<td>To support training of community outreach agents</td>
</tr>
<tr>
<td>3</td>
<td>Benishangul Gumuz</td>
<td>541,700</td>
<td>To support training of community outreach agents</td>
</tr>
<tr>
<td>4</td>
<td>SNNPR</td>
<td>251,370</td>
<td>To support training of health workers at entry point of formerly endemic area (Nyangatom)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Total</strong></td>
<td><strong>3,194,856</strong></td>
</tr>
</tbody>
</table>
SECTION 2
PREVENTIVE CHEMOTHERAPY NTDs
SECTION 2

PREVENTIVE CHEMOTHERAPY NTDS

Background

Preventive chemotherapy is one of the main interventions used by national programmes to control and eliminate five neglected tropical diseases (NTDs): lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases and trachoma. The intervention is through mass drug administration (MDA) and school-based treatments, with the goal of treating populations at risk of infection at appropriate, regular intervals. In order to meet the coverage targets the supply chain must be managed, from planning and quantifying needs, to moving stock from production sites to patients at the service delivery point to communities, schools and hospitals, among others, and to retrieving and accounting for leftover stock. A fundamental step in monitoring the success of programmes is knowing the coverage of preventive chemotherapy.

The Expanded Special Project for the Elimination of NTDs (ESPEN) has been supporting Ethiopia in scaling up and scaling down interventions notably by filling the gaps on Mass Drug Administration (MDA) campaigns, supporting mapping/surveys for PC NTDs and facilitating the PC NTD Medicines donation through the Joint Application Package (JAP).

In 2023 workplan, the WHO country office conducted various activities including quantification and importation of PC medicines for MDA, supported NTD program annual review meeting, conducting integrated supportive supervision for PC NTDs during and after MDA, Supported the MOH to cascade woreda level toolkit on WASH NTD integration.

Key Achievements in 2023

The 2024 Joint Request for Selected PC Medicines (JRSM) and 2022 Joint Report Form (JRF) was supported and timely submitted through the JAP platform. This involves a quantification workshop involving regional NTD managers and implementing partners. Mass
Drug Administration campaigns undertaken for Preventive Chemotherapy NTDs (Onchocerciasis, Lymphatic Filariasis, Soil Transmitted Helminthiasis, Schistosomiasis and Trachoma) in the endemic districts of the country.

The world NTD day was commemorated in Jimma university in collaboration with WHO, Oromia Regional health Bureau and NTD partners. OIC used this opportunity to mobilize resources for NTDs and convened a meeting in WCO with the USDAID mission team.

The quantity of each product imported by WHO summarized in the below table.

<table>
<thead>
<tr>
<th>Product</th>
<th>Quantity imported (tabs)</th>
<th>Remark</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albendazole</td>
<td>3,915,000</td>
<td>For LF MDA</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>35,740,500</td>
<td>For LF and Oncho MDA</td>
</tr>
<tr>
<td>Mebendazole</td>
<td>30,884,000</td>
<td>For STH MDA</td>
</tr>
<tr>
<td>Praziquantel</td>
<td>15,248,000</td>
<td>For SCH MDA</td>
</tr>
</tbody>
</table>
Hosted joint mission a team from WHO AFRO and HQ on country support for WHO-facilitated PC NTD medicines inventory management.

A joint Trachoma/NTD cross border partnership meeting was conducted which convened participants from 12 eastern and southern Africa countries held in Arba Minch town with a theme: Innovation for accelerating elimination. An expert from WHO/ESPEN presented a global overview and updates on trachoma elimination.

NTD review meeting attended by more than one hundred participants held in Hawassa city that pulled-out recommendations to inform the next cycle of annual planning. The DPC Lead Executive Officer, other dignitaries opened this event. On top of this, WHO presented the recommendations formulated by a mission team from AFRO and HQ on improving inventory management of PC NTD medicines.
Regional level advocacy workshop on WASH-NTDs conducted in Sidama region to integrate NTD in WASH program. Woreda (districts) level technical working group and task force team trained on Integrated WASH NTD toolkit for joint monitoring and evaluation of WASH investment for NTDs elimination.

A conference on elimination of trachoma in Ethiopia during the commemoration of world Sight Day was conducted in Sheraton Addis in the presence of different NTD partners. The OIC for WR presented global overview and progress in trachoma elimination.

Commemoration of World sight day through a conference on Trachoma Elimination. Sheraton Addis, October 2023.

KEY ACHIEVEMENTS BY DISEASE

**Lymphatic Filariasis**

WHO country office supported MOH and RHBs to reach over 1.7 million individuals in twenty-eight implementation units using Albendazole plus Ivermectin Mass Drug
Administration (MDA) campaigns. WHO imported 3,915,000 tablets of Albendazole and 35,740,500 tablets of ivermectin.

WHO facilitated the approval of TAS eligibility by AFRO team and request of FTS by MOH. Provided support for LF technical working group meetings at MOH.

**Onchocerciasis**

WHO country office supported MOH and RHBs to reach over 32 million individuals in 273 implementation units using Ivermectin Mass Drug Administration (MDA) campaigns. WHO imported 35,740,500 tablets of ivermectin for (LF and Onchocerciasis). Supported MOH to adapt the WHO entomological manual for onchocerciasis elimination programme. Attended and provided inputs in national onchocerciasis technical working group meetings.

**Schistosomiasis**

WHO country office supported MOH and RHBs to reach over 3.8 million individuals in 169 implementation units using Praziquantel Mass Drug Administration (MDA) campaigns. WHO imported 15,248,000 tablets of Praziquantel. Supported the subdistrict level treatment data in all regions.

**Soil Transmitted Helminthiasis**

WHO country office supported MOH and RHBs to reach over 18 million individuals in 402 implementation units using Mebendazole Mass Drug Administration (MDA) campaigns. WHO imported 30,884,000 tablets of Mebendazole.

**Trachoma**

Over seventeen million individuals reached in 140 implementation units using Azithromycin/TEO Mass Drug Administration (MDA) campaign. Attended and provided support in the national trachoma taskforce meeting.
### Summary of Financial Support

<table>
<thead>
<tr>
<th>S/No.</th>
<th>Direct financial cooperation (DFC)</th>
<th>Purpose</th>
<th>Amount (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Oromia Regional health bureau</td>
<td>Support MOH to celebrate World NTD day</td>
<td>4,980</td>
</tr>
<tr>
<td>2</td>
<td>Sidama regional Health bureau</td>
<td>Support MOH annual NTD program review meeting and WASH tool kit training</td>
<td>30,000</td>
</tr>
<tr>
<td>3</td>
<td>Sidama regional Health bureau</td>
<td>Support WASH tool kit training</td>
<td>10,000</td>
</tr>
<tr>
<td>4</td>
<td>NPO salary</td>
<td>To support an NPO salary</td>
<td>36,696</td>
</tr>
</tbody>
</table>
SECTION 3
CASE MANAGEMENT NTDs
SECTION 3

CASE MANAGEMENT NTDs

BACKGROUND

The WHO country office Ethiopia has been supporting the activities of case management NTDs programs of Ethiopia technically and financially so that the country will achieve the targets set by the WHO NTD Road Map 2021–2030. The technical supports provided include offsite capacity building trainings, onsite coachings of health workers at health facilities and expertise contribution during development of guidelines and manuals. The WHO country office Ethiopia has also actively participated in monitoring and evaluation of the activities of case management NTDs programs of Ethiopia along with Ministry of Health (MoH) and other stakeholders.

In 2023, the WHO country office Ethiopia acquired $219,339 USD from WHO HQ and AFRO to support different activities of the case management NTDs programs of MoH including case finding, diagnosis, and management; provision of medicines and laboratory test kits; capacity building trainings of health workers, conducting implementatinal researches, implanting disease prevention activities, and conducting a national level annual NTDs program performance evaluation meeting besides other activities supported financially.

SUMMARY OF KEY ACHIEVEMENTS:

1. WHO country office Ethiopia supported the supply of medicines and laboratory testing kits for Visceral leishmaniasis, Leprosy and Human African Trypanosomiasis form importation by WHO to distribution to health facilities by Ethiopian Pharmaceutical Supply Service. The medical supplies imported and distributed in 2023 include 20,800 vials of Ambisome; 11,200 tablets of Miltefosine, 4200 vials of Sodium Stibo-Gluconate, 8400 ampouls of Paromomycin and 14,500 rK-39
diagnostic test kits. The provision of these medical supplies contributed to the reduction of Visceral Leishmaniasis case fatality rate to 2%.

2. Capacity building trainings were provided by WHO country office Ethiopia on case management NTDs to 304 health workers and 218 community health extension workers from different regions of Ethiopia as summarized in the table below. These trainings improved the case finding, treatment service and prevention activities of the different case management NTDs supported by capacity building.

<table>
<thead>
<tr>
<th>S.NO</th>
<th>Topic of training</th>
<th>Number of trainees</th>
<th>Regions supported</th>
<th>Remark</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Case management of Visceral Leishmaniasis (VL)</td>
<td>85</td>
<td>SNNPR, South Omo Zone, Somali Region</td>
<td>VL outbreak in South Omo zone of SNNPR</td>
</tr>
<tr>
<td>2</td>
<td>Integrated Noma and Skin NTDs</td>
<td>111</td>
<td>Amhara, Sidama, Somali, Oromia</td>
<td>Primary care workers were trained</td>
</tr>
<tr>
<td>3</td>
<td>Oral health promotion and noma prevention</td>
<td>218</td>
<td>Amhara, Sidama, Somali, Oromia</td>
<td>Community health workers were trained</td>
</tr>
<tr>
<td>4</td>
<td>Human African Trypanosomiasis (HAT)</td>
<td>36</td>
<td>SNNPR, SWER Gambella</td>
<td>HAT outbreak in Gamo Zone of SNNPR</td>
</tr>
<tr>
<td>5</td>
<td>Case management of Cutaneous Leishmaniasis (CL)</td>
<td>72</td>
<td>Somali Oromia</td>
<td>CL outbreak in Somali region</td>
</tr>
</tbody>
</table>

3. WHO country office Ethiopia supported financially and technically meetings and workshops, which include national level annual NTDs program performance
Annual Report _NTDs

evaluation meeting, workshops on leprosy guideline development and national launching workshop on leprosy contact screening and post-exposure prophylaxis.

WHO country office Ethiopia also participated in national, regional and, global technical meetings on case management NTDs including leishmaniasis, leprosy, HAT, skin NTDs and snakebite envenoming.

4. Integrated Supportive Supervision by WHO NTDs officers and regional NTDs officers was conducted at 24 health facilities in Tigray, Afar, SNNP and Somali regions of Ethiopia. During the supportive supervision visit to health facilities, onsite coaching on case management of Visceral Leishmaniasis was provided to 214 health workers. These improved the quality of diagnosis and treatment service of Visceral Leishmaniasis provided by the health facilities resulting in good treatment outcomes.

5. Implementation research activities were supported financially which include a research entitled "Assessment of Skin NTDs burden through community screening during Scabies MDA campaign, SNNPR, Ethiopia" being conducted in collaboration with Collaborative Research Center for NTDs, Arba Minch University. Another research financially supported by WHO and being conducted by Bahir Dar University is on “Mapping and decentralization of diagnosis and treatment of mycetoma and other subcutaneous mycosis in primary health care in Ethiopia.” Arba Minch University is also conducting an assessment study on the risk factors for Visceral Leishmaniasis outbreak in South Omo zone financed by WHO.
### SUMMARY OF FINANCIAL SUPPORT

**219,339** USD was transferred to various institutions by Direct Financial Cooperation (DFC) and Direct Implementation (DI) as indicted in the table below.

<table>
<thead>
<tr>
<th>S.NO</th>
<th>Direct Financial cooperation (DFC)/Direct Implementation (DI)</th>
<th>Purpose</th>
<th>Amount in USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SNNP Regional Health Bureau (DI)</td>
<td>Training on Case management of Visceral Leishmaniasis</td>
<td>8,773</td>
</tr>
<tr>
<td>2</td>
<td>SNNP Regional Health Bureau (DI)</td>
<td>Training and surveillance activities on Human African Trypanosomiasis</td>
<td>19,100</td>
</tr>
<tr>
<td>3</td>
<td>Amhara Regional Health Bureau (DI) Sidama Regional Health Bureau (DFC) Oromia Regional Health Bureau (DFC) Somali Regional Health Bureau (DFC)</td>
<td>Training on Integrated Noma, Skin NTDs and oral health promotion</td>
<td>64,000</td>
</tr>
<tr>
<td>4</td>
<td>Oromia Regional Health Bureau (DFC) Amhara Regional Health Bureau (DFC)</td>
<td>Leprosy contact screening and PEP</td>
<td>45,000</td>
</tr>
<tr>
<td>5</td>
<td>Somali Regional Health Bureau (DFC)</td>
<td>Training on Case management of Cutaneous Leishmaniasis</td>
<td>18,000</td>
</tr>
<tr>
<td>6</td>
<td>Arba Minch University (DFC)</td>
<td>Research on skin NTDs assessment</td>
<td>24,466</td>
</tr>
<tr>
<td>7</td>
<td>Bahir Dar University (DFC)</td>
<td>Research on mapping of Mycetoma</td>
<td>20,000</td>
</tr>
<tr>
<td>8</td>
<td>Arba Minch University (DFC)</td>
<td>Research on study on the risk factors for VL outbreak in South Omo zone</td>
<td>20,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>219,339</strong></td>
</tr>
</tbody>
</table>
**56,892 USD** used for staff salary/data officer and CM NTDs officer at the WHO Country office

**6,800 USD** used for medical supplies expense/settling custom clearances

**250,000 USD** mobilized from WCO Emergency Program for procurement of medicines and test kits for Visceral Leishmaniasis needed for Ethiopia in the year 2024.

### Action Pictures

Onsite coaching on Leishmaniasis by WHO NTDs officer to health workers in Gode Primary Hospital, Somali Region, September 2023.

Meeting of WHO HQ scientist, Dr Saurabh, and WHO NTDs officers with health workers from Jinka Primary Hospital Visceral Leishmaniasis Treatment Center

Onsite coaching on Leprosy by WHO NTDs officer to health workers in Fik Primary Hospital, Somali Region, December 2023

Training on integrated Noma and skin NTDs for primary care health workers from Somali Region, November 2023